Aim: To analyze the influence of pharmacogenetic factors on the risk of clopidogrel resistance and cardiovascular events during 18-months follow-up.
Subjects And Methods: Two hundred and fifty patients taking clopidogrel were examined. Platelet function was determined by optical aggregometry.